Public-domain · open source
OpenJurist
← 222 F.3d 973 - Eli Lilly And Company v. Barr Laboratories, Inc.

Eli Lilly And Company v. Barr Laboratories, Inc.’s Empirical Analysis

222 F.3d 973 · 2000

Citation profile

11
cited by 11 later decisions
June 2003
most recently cited

3 district ·

Relationships

Relies on Anderson v. Liberty Lobby, Inc. · Miller v. Eagle Manuf'G Co · Hybritech Inc. v. Monoclonal Antibodies, Inc. · Scripps Clinic & Research Foundation v. Genentech, Inc. · Conroy v. Reebok International, Ltd.

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 11 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “) and Klaus K. Schmiegel as inventors. After its filing, the '379 application engendered a progeny of divisional applications, continuation applications, and patents that rivals the Hapsburg legacy. When the last patent stemming from the '379 application issued in December 1986, the application had spawned four divisional applications, three continuation applications, and six patents. During that twelve-year period, Lilly obtained six patents relating to fluoxetine hydrochloride the '081 and '549 patents, as well as U.S. Patent Nos. 4,018,895 (”
    1 later decision quote this exact passage · from the majority
  2. “) to devise a cost-efficient method of synthesizing p-trifluoromethylphenol. After experimenting with various prior art methods, Molloy concluded that those methods were inadequate for generating a sufficient amount of p-trifluoromethylphenol for use in clinical testing. Then, following further research, Molloy and Lavagnino developed their own method for preparing p-trifluoromethylphenol that, as Lavagnino described in his deposition, was”
    1 later decision quote this exact passage · from the majority
  3. “) and claim 7 the '549 patent. Lilly subsequently brought infringement actions against Geneva Pharmaceuticals, Inc., Apotex, Inc., and Bernard C. Sherman, all of whom had also filed ANDA applications with the FDA, and the actions were consolidated. 3 Barr and the other defendants (collectively”
    1 later decision quote this exact passage · from the majority

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.